Pub Date : 2025-03-05DOI: 10.1001/jamapsychiatry.2025.0013
Matheus Rassi F Ramos, Stephan Goerigk, Valquiria Aparecida da Silva, Beatriz Araújo Cavendish, Bianca Silva Pinto, Cássio Henrique Gomide Papa, João Vitor Resende, Izio Klein, Adriana Munhoz Carneiro, Juliana Pereira de Sousa, Kallene Summer Moreira Vidal, Leandro da Costa Lane Valiengo, Lais B Razza, Luana Marotti Aparício, Lisiane Martins, Lucas Borrione, Mariana Batista, Natasha Kouvalesk Moran, Leonardo Afonso Dos Santos, Rafael Benatti, Rebeca Pelosof, Frank Padberg, Andre R Brunoni
Importance: Intermittent theta-burst stimulation (iTBS) is an established treatment for treatment-resistant depression (TRD). Sessions conducted more than once daily (ie, accelerated TBS [aTBS]) may enhance antidepressant effects. However, evidence is limited to small trials, and protocols are time-consuming and can require neuroimaging-based targeting.
Objective: To evaluate the efficacy and safety of a pragmatic aTBS protocol for TRD.
Design, setting, and participants: This triple-blinded, sham-controlled randomized clinical trial was conducted at a single center in São Paulo, Brazil, from July 2022 to June 2024, with a subsequent open-label phase. Patients aged 18 to 65 years with major depression, experiencing a TRD episode, and with a Hamilton Depression Rating Scale, 17-item (HDRS-17) score of 17 or higher were eligible for inclusion. Exclusion criteria were other psychiatric disorders (except anxiety), neurological conditions, and TBS contraindications.
Interventions: Participants received 45 active or sham stimulation sessions over 15 weekdays, with 3 iTBS sessions (1200 pulses each) per day, spaced 30 minutes apart and targeting the left dorsolateral prefrontal cortex using a craniometric approach. In the open-label phase, additional aTBS sessions were offered to achieve a response (≥50% HDRS-17 score improvement) if needed.
Main outcomes and measures: The primary outcome was change in HDRS-17 score at week 5.
Results: Of 431 volunteers screened, 100 participants were enrolled and randomized to either sham or active aTBS. Mean (SD) participant age was 41.7 (8.8) years, and 84 participants (84%) were female. A total of 89 patients completed the study. In the intention-to-treat analysis, the mean change in HDRS-17 scores from baseline to the study end point was 5.57 (95% CI, 3.99-7.16) in the sham group and 9.68 (95% CI, 8.11-11.25) in the active group, corresponding to 31.87% and 54.7% score reductions, respectively, and a medium-to-large effect size (Cohen d, 0.65; 95% CI, 0.29-1.00; P < .001). Response and remission rates were also higher in the active group. Both interventions were well tolerated, but scalp pain was more frequent in the active group than the sham group (17.4% vs 4.4%). During the open-label phase, approximately 75% of patients received additional sessions.
Conclusions and relevance: In this triple-blinded, sham-controlled randomized clinical trial, a pragmatic aTBS protocol using only 3 iTBS sessions per day and a nonexpensive, non-neuronavigated approach was found to be safe and effective for TRD.
{"title":"Accelerated Theta-Burst Stimulation for Treatment-Resistant Depression: A Randomized Clinical Trial.","authors":"Matheus Rassi F Ramos, Stephan Goerigk, Valquiria Aparecida da Silva, Beatriz Araújo Cavendish, Bianca Silva Pinto, Cássio Henrique Gomide Papa, João Vitor Resende, Izio Klein, Adriana Munhoz Carneiro, Juliana Pereira de Sousa, Kallene Summer Moreira Vidal, Leandro da Costa Lane Valiengo, Lais B Razza, Luana Marotti Aparício, Lisiane Martins, Lucas Borrione, Mariana Batista, Natasha Kouvalesk Moran, Leonardo Afonso Dos Santos, Rafael Benatti, Rebeca Pelosof, Frank Padberg, Andre R Brunoni","doi":"10.1001/jamapsychiatry.2025.0013","DOIUrl":"10.1001/jamapsychiatry.2025.0013","url":null,"abstract":"<p><strong>Importance: </strong>Intermittent theta-burst stimulation (iTBS) is an established treatment for treatment-resistant depression (TRD). Sessions conducted more than once daily (ie, accelerated TBS [aTBS]) may enhance antidepressant effects. However, evidence is limited to small trials, and protocols are time-consuming and can require neuroimaging-based targeting.</p><p><strong>Objective: </strong>To evaluate the efficacy and safety of a pragmatic aTBS protocol for TRD.</p><p><strong>Design, setting, and participants: </strong>This triple-blinded, sham-controlled randomized clinical trial was conducted at a single center in São Paulo, Brazil, from July 2022 to June 2024, with a subsequent open-label phase. Patients aged 18 to 65 years with major depression, experiencing a TRD episode, and with a Hamilton Depression Rating Scale, 17-item (HDRS-17) score of 17 or higher were eligible for inclusion. Exclusion criteria were other psychiatric disorders (except anxiety), neurological conditions, and TBS contraindications.</p><p><strong>Interventions: </strong>Participants received 45 active or sham stimulation sessions over 15 weekdays, with 3 iTBS sessions (1200 pulses each) per day, spaced 30 minutes apart and targeting the left dorsolateral prefrontal cortex using a craniometric approach. In the open-label phase, additional aTBS sessions were offered to achieve a response (≥50% HDRS-17 score improvement) if needed.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was change in HDRS-17 score at week 5.</p><p><strong>Results: </strong>Of 431 volunteers screened, 100 participants were enrolled and randomized to either sham or active aTBS. Mean (SD) participant age was 41.7 (8.8) years, and 84 participants (84%) were female. A total of 89 patients completed the study. In the intention-to-treat analysis, the mean change in HDRS-17 scores from baseline to the study end point was 5.57 (95% CI, 3.99-7.16) in the sham group and 9.68 (95% CI, 8.11-11.25) in the active group, corresponding to 31.87% and 54.7% score reductions, respectively, and a medium-to-large effect size (Cohen d, 0.65; 95% CI, 0.29-1.00; P < .001). Response and remission rates were also higher in the active group. Both interventions were well tolerated, but scalp pain was more frequent in the active group than the sham group (17.4% vs 4.4%). During the open-label phase, approximately 75% of patients received additional sessions.</p><p><strong>Conclusions and relevance: </strong>In this triple-blinded, sham-controlled randomized clinical trial, a pragmatic aTBS protocol using only 3 iTBS sessions per day and a nonexpensive, non-neuronavigated approach was found to be safe and effective for TRD.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT05388539.</p>","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":""},"PeriodicalIF":22.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-05DOI: 10.1001/jamapsychiatry.2025.0024
Joshua B Grubbs, Alexander J Connolly, Scott Graupensperger, Hyoun S Kim, Shane W Kraus
Importance: Sports gambling has become one of the most accessible forms of gambling in the United States, and recent research suggests that sports gambling coupled with frequent alcohol use may have deleterious health consequences.
Objective: To examine the trajectories of sports gambling frequency and alcohol-related problems over time and the associations between these trajectories.
Design, setting, and participants: This survey study was a 2-year longitudinal study conducted in the United States. Participants were recruited from a nonprobability internet panel from 2 sources: a large cross-section of adults matched and weighted to US Census norms and a specific oversample of sports-gambling adults. Recruitment began in spring 2022, and the last surveys concluded in spring 2024. To identify trajectories within sports gambling frequency and alcohol use problems, latent growth curve modeling was used.
Main outcomes: At each time point, the National Institute on Drug Abuse-modified Alcohol, Smoking, and Substance Involvement Screening Test 2 was used to assess alcohol-related problems and sports gambling frequency was assessed by a single item.
Results: The cross-section of US adults (n = 2806) and oversample of sports-gambling adults (n = 1557) resulted in a total baseline sample of 4363 (mean [SD] age, 49.6 [16.2] years; 2243 men [51.4%] and 2120 women or nonbinary gender reported [48.6%]). Latent growth curve modeling revealed that alcohol problems decreased over time (slope = -0.059; 95% CI, -0.090 to -0.028). Sports gambling frequency did not show a significant trend over time (slope = -0.003; 95% CI, -0.053 to 0.047), though there was significant variance in this slope (variance = 0.024; 95% CI, 0.013 to 0.034). The trajectories of alcohol-related problems and sports gambling did not move independently, instead being highly positively correlated, suggesting that increases in one would correspond to increases in the other.
Conclusions and relevance: This study found that over time, the trajectory of sports gambling frequency was associated with the trajectory of alcohol-related problems. Screening and treatment interventions are recommended for sport gamblers who also drink concurrently, especially because this group appears to be at an elevated risk for developing greater alcohol-related problems over time.
{"title":"Sports Gambling and Drinking Behaviors Over Time.","authors":"Joshua B Grubbs, Alexander J Connolly, Scott Graupensperger, Hyoun S Kim, Shane W Kraus","doi":"10.1001/jamapsychiatry.2025.0024","DOIUrl":"10.1001/jamapsychiatry.2025.0024","url":null,"abstract":"<p><strong>Importance: </strong>Sports gambling has become one of the most accessible forms of gambling in the United States, and recent research suggests that sports gambling coupled with frequent alcohol use may have deleterious health consequences.</p><p><strong>Objective: </strong>To examine the trajectories of sports gambling frequency and alcohol-related problems over time and the associations between these trajectories.</p><p><strong>Design, setting, and participants: </strong>This survey study was a 2-year longitudinal study conducted in the United States. Participants were recruited from a nonprobability internet panel from 2 sources: a large cross-section of adults matched and weighted to US Census norms and a specific oversample of sports-gambling adults. Recruitment began in spring 2022, and the last surveys concluded in spring 2024. To identify trajectories within sports gambling frequency and alcohol use problems, latent growth curve modeling was used.</p><p><strong>Main outcomes: </strong>At each time point, the National Institute on Drug Abuse-modified Alcohol, Smoking, and Substance Involvement Screening Test 2 was used to assess alcohol-related problems and sports gambling frequency was assessed by a single item.</p><p><strong>Results: </strong>The cross-section of US adults (n = 2806) and oversample of sports-gambling adults (n = 1557) resulted in a total baseline sample of 4363 (mean [SD] age, 49.6 [16.2] years; 2243 men [51.4%] and 2120 women or nonbinary gender reported [48.6%]). Latent growth curve modeling revealed that alcohol problems decreased over time (slope = -0.059; 95% CI, -0.090 to -0.028). Sports gambling frequency did not show a significant trend over time (slope = -0.003; 95% CI, -0.053 to 0.047), though there was significant variance in this slope (variance = 0.024; 95% CI, 0.013 to 0.034). The trajectories of alcohol-related problems and sports gambling did not move independently, instead being highly positively correlated, suggesting that increases in one would correspond to increases in the other.</p><p><strong>Conclusions and relevance: </strong>This study found that over time, the trajectory of sports gambling frequency was associated with the trajectory of alcohol-related problems. Screening and treatment interventions are recommended for sport gamblers who also drink concurrently, especially because this group appears to be at an elevated risk for developing greater alcohol-related problems over time.</p>","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":""},"PeriodicalIF":22.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-05DOI: 10.1001/jamapsychiatry.2024.4941
Leon Dudeck, Madeleine Nussbaumer, Thomas Nickl-Jockschat, Paul C Guest, Henrik Dobrowolny, Gabriela Meyer-Lotz, Zhongming Zhao, Roland Jacobs, Kolja Schiltz, Brisa S Fernandes, Johann Steiner
<p><strong>Importance: </strong>This study aims to provide robust evidence to support or challenge the immune hypothesis of schizophrenia.</p><p><strong>Objective: </strong>To conduct a meta-analysis of reports on blood leukocyte subpopulations in schizophrenia vs healthy controls, examining disease- and treatment-related differences as well as potential confounders.</p><p><strong>Data sources: </strong>Systematic database search for English and non-English peer-reviewed articles in PubMed, Web of Science, Scopus, and Cochrane Library databases, with the last search in January 2024.</p><p><strong>Study selection: </strong>Cross-sectional, case-control, and longitudinal studies comparing leukocyte numbers in patients with schizophrenia and healthy controls. After duplicates were removed, 3691 studies were identified for screening.</p><p><strong>Data extraction and synthesis: </strong>Data extraction and quality assessment were conducted following PRISMA and MOOSE guidelines. Data were independently extracted by 2 authors and pooled using random-effects models.</p><p><strong>Main outcomes and measures: </strong>The planned primary outcomes were differences in leukocyte subpopulation counts between individuals with schizophrenia and healthy controls to increase our understanding of the immune system dysfunction in schizophrenia.</p><p><strong>Results: </strong>Sixty-four relevant articles were identified (60 cross-sectional/case-control studies and 4 longitudinal studies) with data on leukocyte numbers from 26 349 individuals with schizophrenia and 16 379 healthy controls. Neutrophils (g = 0.69; 95% CI, 0.49 to 0.89; Bonferroni-adjusted P < .001; n = 40 951 [47 between-group comparisons]) and monocytes (g = 0.49; 95% CI, 0.24 to 0.75; Bonferroni-adjusted P < .001; n = 40 513 [44 between-group comparisons]) were higher in schizophrenia compared with control participants. Differences were greater in first-episode vs chronic schizophrenia and in patients who were not treated vs treated with antipsychotic medication. There were no significant differences in eosinophils (g = 0.02; 95% CI, -0.16 to 0.20; Bonferroni-adjusted P > .99; n = 3277 [18 between-group comparisons]), basophils (g = 0.14; 95% CI, -0.06 to 0.34; Bonferroni-adjusted P = .85; n = 2614 [13 between-group comparisons]), or lymphocytes (g = -0.08; 95% CI, -0.21 to 0.06; Bonferroni-adjusted P > .99; n = 41 693 [59 between-group comparisons]). Neutrophils decreased longitudinally (g = -0.30; 95% CI, -0.45 to -0.15; Bonferroni-adjusted P < .001; n = 896 [4 within-group comparisons]) and eosinophils increased longitudinally (g = 0.61; 95% CI, 0.52 to 0.71; Bonferroni-adjusted P < .001; n = 876 [3 within-group comparisons]) after successful treatment of acute psychosis.</p><p><strong>Conclusions and relevance: </strong>Our findings of increased blood neutrophils and monocytes support the immune hypothesis of schizophrenia, particularly highlighting the role of innate immune activation. As these
{"title":"Differences in Blood Leukocyte Subpopulations in Schizophrenia: A Systematic Review and Meta-Analysis.","authors":"Leon Dudeck, Madeleine Nussbaumer, Thomas Nickl-Jockschat, Paul C Guest, Henrik Dobrowolny, Gabriela Meyer-Lotz, Zhongming Zhao, Roland Jacobs, Kolja Schiltz, Brisa S Fernandes, Johann Steiner","doi":"10.1001/jamapsychiatry.2024.4941","DOIUrl":"10.1001/jamapsychiatry.2024.4941","url":null,"abstract":"<p><strong>Importance: </strong>This study aims to provide robust evidence to support or challenge the immune hypothesis of schizophrenia.</p><p><strong>Objective: </strong>To conduct a meta-analysis of reports on blood leukocyte subpopulations in schizophrenia vs healthy controls, examining disease- and treatment-related differences as well as potential confounders.</p><p><strong>Data sources: </strong>Systematic database search for English and non-English peer-reviewed articles in PubMed, Web of Science, Scopus, and Cochrane Library databases, with the last search in January 2024.</p><p><strong>Study selection: </strong>Cross-sectional, case-control, and longitudinal studies comparing leukocyte numbers in patients with schizophrenia and healthy controls. After duplicates were removed, 3691 studies were identified for screening.</p><p><strong>Data extraction and synthesis: </strong>Data extraction and quality assessment were conducted following PRISMA and MOOSE guidelines. Data were independently extracted by 2 authors and pooled using random-effects models.</p><p><strong>Main outcomes and measures: </strong>The planned primary outcomes were differences in leukocyte subpopulation counts between individuals with schizophrenia and healthy controls to increase our understanding of the immune system dysfunction in schizophrenia.</p><p><strong>Results: </strong>Sixty-four relevant articles were identified (60 cross-sectional/case-control studies and 4 longitudinal studies) with data on leukocyte numbers from 26 349 individuals with schizophrenia and 16 379 healthy controls. Neutrophils (g = 0.69; 95% CI, 0.49 to 0.89; Bonferroni-adjusted P < .001; n = 40 951 [47 between-group comparisons]) and monocytes (g = 0.49; 95% CI, 0.24 to 0.75; Bonferroni-adjusted P < .001; n = 40 513 [44 between-group comparisons]) were higher in schizophrenia compared with control participants. Differences were greater in first-episode vs chronic schizophrenia and in patients who were not treated vs treated with antipsychotic medication. There were no significant differences in eosinophils (g = 0.02; 95% CI, -0.16 to 0.20; Bonferroni-adjusted P > .99; n = 3277 [18 between-group comparisons]), basophils (g = 0.14; 95% CI, -0.06 to 0.34; Bonferroni-adjusted P = .85; n = 2614 [13 between-group comparisons]), or lymphocytes (g = -0.08; 95% CI, -0.21 to 0.06; Bonferroni-adjusted P > .99; n = 41 693 [59 between-group comparisons]). Neutrophils decreased longitudinally (g = -0.30; 95% CI, -0.45 to -0.15; Bonferroni-adjusted P < .001; n = 896 [4 within-group comparisons]) and eosinophils increased longitudinally (g = 0.61; 95% CI, 0.52 to 0.71; Bonferroni-adjusted P < .001; n = 876 [3 within-group comparisons]) after successful treatment of acute psychosis.</p><p><strong>Conclusions and relevance: </strong>Our findings of increased blood neutrophils and monocytes support the immune hypothesis of schizophrenia, particularly highlighting the role of innate immune activation. As these","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":""},"PeriodicalIF":22.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1001/jamapsychiatry.2024.4483
Artur Menegaz de Almeida, Francisco Cezar Aquino Moraes, Francinny Alves Kelly
{"title":"Bright Light Therapy for Nonseasonal Depressive Disorders-Reply.","authors":"Artur Menegaz de Almeida, Francisco Cezar Aquino Moraes, Francinny Alves Kelly","doi":"10.1001/jamapsychiatry.2024.4483","DOIUrl":"10.1001/jamapsychiatry.2024.4483","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"324-325"},"PeriodicalIF":22.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1001/jamapsychiatry.2024.4462
Jennifer Y F Lau, Stefan Priebe, Craig Morgan
{"title":"Social Health and Serious Mental Illness-A Step Forward?","authors":"Jennifer Y F Lau, Stefan Priebe, Craig Morgan","doi":"10.1001/jamapsychiatry.2024.4462","DOIUrl":"10.1001/jamapsychiatry.2024.4462","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"213-214"},"PeriodicalIF":22.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1001/jamapsychiatry.2024.4145
Jayani Jayawardhana, Jialin Hou, Patricia Freeman, Jeffery C Talbert
<p><strong>Importance: </strong>Whether state implementation of medical and recreational cannabis laws is associated with increased cannabis use disorder (CUD) and/or cannabis poisoning among adults is not evident.</p><p><strong>Objective: </strong>To examine state-level medical and recreational cannabis laws' associations with CUD and cannabis poisoning, overall and by sex and age subgroups.</p><p><strong>Design, setting, and participants: </strong>In this longitudinal cohort study, state-level CUD and cannabis poisoning diagnoses from January 2011 to December 2021 were examined across all 50 US states and the District of Columbia before and after the implementation of medical and recreational cannabis laws (MCLs and RCLs, respectively) using a staggered adoption difference-in-differences approach. Event studies were conducted to estimate the magnitude of the association for each year-quarter relative to the time of each policy implementation. This study was conducted among all adults aged 18 to 64 years enrolled in the Merative MarketScan Commercial Claims and Encounters Database, a database of employer-sponsored health insurance enrollees, with 1 year or more of continuous enrollment from 2011 to 2021. Data analysis was performed from January to August 2024.</p><p><strong>Exposures: </strong>State implementation of an MCL, opening a medical cannabis dispensary (MCD), allowing home cultivation of medical cannabis (HC-MC), and passage of an RCL.</p><p><strong>Main outcomes and measures: </strong>CUD and cannabis poisoning diagnoses per 100 000 enrollees per quarter.</p><p><strong>Results: </strong>This study included 110 256 536 enrollees, of whom 56 843 030 (52%) were female and the mean (SD) enrollee age was 41.0 (13.5) years. MCLs were associated with significant increases in CUD and cannabis poisoning by 31.09 (95% CI, 20.20-41.99; P < .001) and 0.76 (95% CI, 0.52-1.00; P < .001) diagnoses per 100 000 enrollees per quarter, respectively, and RCLs were associated with a significant increase in cannabis poisoning by 0.34 (95% CI, 0.19-0.48; P < .001) per 100 000 enrollees per quarter in states with RCLs compared to states without these laws. No significant associations were observed for MCDs or HC-MC. Relative increases in CUD associated with MCLs were higher among female enrollees and among enrollees aged 35 to 44 years compared with male enrollees and other age groups, respectively. Sensitivity analysis results of 2011 to 2019 data were consistent with the 2011 to 2021 results.</p><p><strong>Conclusions and relevance: </strong>In this longitudinal cohort study, MCLs were associated with increased CUD and cannabis poisoning diagnoses, and RCLs were associated with increased cannabis poisoning in adults aged 18 to 64 years with employer-sponsored health insurance. Communities with increased access to cannabis may experience increased health care use and costs due to increases in cannabis poisoning and CUD, and new clinical and policy intervent
{"title":"Association of State Cannabis Legalization With Cannabis Use Disorder and Cannabis Poisoning.","authors":"Jayani Jayawardhana, Jialin Hou, Patricia Freeman, Jeffery C Talbert","doi":"10.1001/jamapsychiatry.2024.4145","DOIUrl":"10.1001/jamapsychiatry.2024.4145","url":null,"abstract":"<p><strong>Importance: </strong>Whether state implementation of medical and recreational cannabis laws is associated with increased cannabis use disorder (CUD) and/or cannabis poisoning among adults is not evident.</p><p><strong>Objective: </strong>To examine state-level medical and recreational cannabis laws' associations with CUD and cannabis poisoning, overall and by sex and age subgroups.</p><p><strong>Design, setting, and participants: </strong>In this longitudinal cohort study, state-level CUD and cannabis poisoning diagnoses from January 2011 to December 2021 were examined across all 50 US states and the District of Columbia before and after the implementation of medical and recreational cannabis laws (MCLs and RCLs, respectively) using a staggered adoption difference-in-differences approach. Event studies were conducted to estimate the magnitude of the association for each year-quarter relative to the time of each policy implementation. This study was conducted among all adults aged 18 to 64 years enrolled in the Merative MarketScan Commercial Claims and Encounters Database, a database of employer-sponsored health insurance enrollees, with 1 year or more of continuous enrollment from 2011 to 2021. Data analysis was performed from January to August 2024.</p><p><strong>Exposures: </strong>State implementation of an MCL, opening a medical cannabis dispensary (MCD), allowing home cultivation of medical cannabis (HC-MC), and passage of an RCL.</p><p><strong>Main outcomes and measures: </strong>CUD and cannabis poisoning diagnoses per 100 000 enrollees per quarter.</p><p><strong>Results: </strong>This study included 110 256 536 enrollees, of whom 56 843 030 (52%) were female and the mean (SD) enrollee age was 41.0 (13.5) years. MCLs were associated with significant increases in CUD and cannabis poisoning by 31.09 (95% CI, 20.20-41.99; P < .001) and 0.76 (95% CI, 0.52-1.00; P < .001) diagnoses per 100 000 enrollees per quarter, respectively, and RCLs were associated with a significant increase in cannabis poisoning by 0.34 (95% CI, 0.19-0.48; P < .001) per 100 000 enrollees per quarter in states with RCLs compared to states without these laws. No significant associations were observed for MCDs or HC-MC. Relative increases in CUD associated with MCLs were higher among female enrollees and among enrollees aged 35 to 44 years compared with male enrollees and other age groups, respectively. Sensitivity analysis results of 2011 to 2019 data were consistent with the 2011 to 2021 results.</p><p><strong>Conclusions and relevance: </strong>In this longitudinal cohort study, MCLs were associated with increased CUD and cannabis poisoning diagnoses, and RCLs were associated with increased cannabis poisoning in adults aged 18 to 64 years with employer-sponsored health insurance. Communities with increased access to cannabis may experience increased health care use and costs due to increases in cannabis poisoning and CUD, and new clinical and policy intervent","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"228-236"},"PeriodicalIF":22.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1001/jamapsychiatry.2024.4475
Beth Han, Wilson M Compton, Emily B Einstein, Nora D Volkow
{"title":"Medically Recommended vs Nonmedical Cannabis Use Among US Adults.","authors":"Beth Han, Wilson M Compton, Emily B Einstein, Nora D Volkow","doi":"10.1001/jamapsychiatry.2024.4475","DOIUrl":"10.1001/jamapsychiatry.2024.4475","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"319-321"},"PeriodicalIF":22.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1001/jamapsychiatry.2024.4216
Manan Arora, Henry Chase, Michele A Bertocci, Alexander S Skeba, Kristen Eckstrand, Genna Bebko, Haris A Aslam, Robert Raeder, Simona Graur, Osasumwen Benjamin, Yiming Wang, Richelle S Stiffler, Mary L Phillips
<p><strong>Importance: </strong>Mania/hypomania is the pathognomonic feature of bipolar disorder (BD). As BD is often misdiagnosed as major depressive disorder (MDD), replicable neural markers of mania/hypomania risk are needed for earlier BD diagnosis and pathophysiological treatment development.</p><p><strong>Objective: </strong>To replicate the previously reported positive association between left ventrolateral prefrontal cortex (vlPFC) activity during reward expectancy (RE) and mania/hypomania risk, to explore the effect of MDD history on this association, and to compare RE-related left vlPFC activity in individuals with and at risk of BD.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study was conducted from July 2014 to December 2023 at the University of Pittsburgh, Pittsburgh, Pennsylvania. Three samples were formed comprising young adults (aged 18 to 30 years) without BD and with a range of subsyndromal-syndromal affective and anxiety psychopathologies, including a new sample and 2 test samples from our previous research; a sample of individuals aged 18 to 30 years with euthymic BD was also included. All participants were recruited from the community through advertising.</p><p><strong>Exposures: </strong>Functional magnetic resonance imaging during an RE task.</p><p><strong>Main outcomes and measures: </strong>New sample: whole-brain activity during RE regressed to the Mood Spectrum Self-Report Lifetime Questionnaire (MOODS-SR-L) manic domain score in all participants and in those without history of MDD and RE-related whole-brain activity regressed to the MOODS-SR-L depressive domain score to determine specificity to mania/hypomania risk. Test samples: these associations were examined using parameter estimates of activity extracted from respective masks created from activity in the new sample. A tertile split of MOODS-SR-L manic domain score divided the new sample into 3 mania/hypomania risk groups. Comparison of RE-related activity (extracted parameter estimates) was performed in risk groups and individuals with BD.</p><p><strong>Results: </strong>Among the 113 individuals in the new sample, 73 were female, and the mean (SD) age was 23.88 (3.32) years. In each of the test samples, there were 52 individuals (39 female; mean [SD] age, 21.94 [2.12] years) and 65 individuals (47 female; mean [SD] age, 21.39 [2.11] years). The euthymic BD group had 37 individuals (30 female; mean [SD] age, 25.12 [3.81] years). In the new sample, 8 clusters of RE-related activity, including left vlPFC activity, showed a positive association with mania/hypomania risk, which remained after excluding individuals with MDD history and was specific to mania/hypomania risk. In the test samples, this association was shown in test sample 1 only (β, 0.21; 95% CI, 0.08-0.35; P = .002; q(false discovery rate [FDR]), 0.006; R2, 0.04). Test sample 2 had a higher proportion with MDD history (49 of 65 [75.3%] compared to 31 of 52 [59.6%] in sa
重要性:躁狂/轻躁狂是双相情感障碍(BD)的病理特征。由于双相障碍常被误诊为重度抑郁症(MDD),因此需要可复制的躁狂症/轻躁症风险神经标志物来进行早期诊断和病理生理治疗。目的:重复先前报道的奖励预期(RE)期间左腹外侧前额叶皮质(vlPFC)活动与躁狂/轻躁狂风险之间的正相关,探讨重度抑郁症病史对这种关联的影响,并比较有和有bd风险的个体中与RE相关的左腹外侧前额叶皮质(vlPFC)活动。设计、环境和参与者:这项横切研究于2014年7月至2023年12月在宾夕法尼亚州匹兹堡市匹兹堡大学进行。三个样本由没有双相障碍的年轻人(18至30岁)组成,他们具有一系列亚综合征-综合征情感和焦虑精神病理学,包括一个新样本和两个来自我们之前研究的测试样本;年龄在18到30岁之间的常郁双相障碍患者也被纳入研究对象。所有的参与者都是通过广告从社区中招募的。暴露:功能磁共振成像在RE任务期间。主要结果和测量方法:新样本:所有参与者在RE期间的全脑活动回归到情绪谱自我报告终生问卷(mods - sr - l)躁狂域评分,无MDD病史的参与者和RE相关的全脑活动回归到mods - sr - l抑郁域评分,以确定躁狂/轻躁狂风险的特异性。测试样本:使用从新样本中的活动创建的各自掩模中提取的活动参数估计来检查这些关联。mods - sr - l躁狂域评分分五分之一将新样本分为3个躁狂/轻躁狂风险组。比较危险组和bd个体的re相关活性(提取参数估计)。结果:新样本113例中,73例为女性,平均(SD)年龄为23.88(3.32)岁。在每个测试样本中,有52个个体(39个女性;平均[SD]年龄21.94[2.12]岁),65例(女性47例;平均[SD]年龄21.39[2.11]岁)。良性BD组37例(女性30例;平均[SD]年龄25.12[3.81]岁)。在新样本中,包括左vlPFC活动在内的8个re相关活动簇显示与躁狂症/轻躁症风险呈正相关,在排除有重度抑郁症病史的个体后仍然存在,并且特定于躁狂症/轻躁症风险。在测试样本中,这种关联仅在测试样本1中显示(β, 0.21;95% ci, 0.08-0.35;p = .002;q(错误发现率[FDR]), 0.006;R2, 0.04)。测试样本2有重度抑郁症病史的比例更高(65人中有49人[75.3%],而样本1中有31人[59.6%])。将两个测试样本中没有重度抑郁症病史的个体结合起来,证实了这一关联(β, 0.32;95% ci, 0.08-0.58;p = .01;问(罗斯福),0.023;R2, 0.02)。风险最高的个体与风险最低的个体相比,re相关的左vlPFC活动显著增加(Cohen d, 1.01;95% ci, 0.29-0.79;结论和相关性:re相关的左vlPFC活动升高与躁狂/轻躁狂风险相关,并因重度抑郁症病史而减弱。这些发现提供了一个神经靶点,以帮助开发患有或有躁狂/轻躁狂风险的个体的病理生理干预。
{"title":"Left Ventrolateral Prefrontal Cortical Activity During Reward Expectancy and Mania Risk.","authors":"Manan Arora, Henry Chase, Michele A Bertocci, Alexander S Skeba, Kristen Eckstrand, Genna Bebko, Haris A Aslam, Robert Raeder, Simona Graur, Osasumwen Benjamin, Yiming Wang, Richelle S Stiffler, Mary L Phillips","doi":"10.1001/jamapsychiatry.2024.4216","DOIUrl":"10.1001/jamapsychiatry.2024.4216","url":null,"abstract":"<p><strong>Importance: </strong>Mania/hypomania is the pathognomonic feature of bipolar disorder (BD). As BD is often misdiagnosed as major depressive disorder (MDD), replicable neural markers of mania/hypomania risk are needed for earlier BD diagnosis and pathophysiological treatment development.</p><p><strong>Objective: </strong>To replicate the previously reported positive association between left ventrolateral prefrontal cortex (vlPFC) activity during reward expectancy (RE) and mania/hypomania risk, to explore the effect of MDD history on this association, and to compare RE-related left vlPFC activity in individuals with and at risk of BD.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study was conducted from July 2014 to December 2023 at the University of Pittsburgh, Pittsburgh, Pennsylvania. Three samples were formed comprising young adults (aged 18 to 30 years) without BD and with a range of subsyndromal-syndromal affective and anxiety psychopathologies, including a new sample and 2 test samples from our previous research; a sample of individuals aged 18 to 30 years with euthymic BD was also included. All participants were recruited from the community through advertising.</p><p><strong>Exposures: </strong>Functional magnetic resonance imaging during an RE task.</p><p><strong>Main outcomes and measures: </strong>New sample: whole-brain activity during RE regressed to the Mood Spectrum Self-Report Lifetime Questionnaire (MOODS-SR-L) manic domain score in all participants and in those without history of MDD and RE-related whole-brain activity regressed to the MOODS-SR-L depressive domain score to determine specificity to mania/hypomania risk. Test samples: these associations were examined using parameter estimates of activity extracted from respective masks created from activity in the new sample. A tertile split of MOODS-SR-L manic domain score divided the new sample into 3 mania/hypomania risk groups. Comparison of RE-related activity (extracted parameter estimates) was performed in risk groups and individuals with BD.</p><p><strong>Results: </strong>Among the 113 individuals in the new sample, 73 were female, and the mean (SD) age was 23.88 (3.32) years. In each of the test samples, there were 52 individuals (39 female; mean [SD] age, 21.94 [2.12] years) and 65 individuals (47 female; mean [SD] age, 21.39 [2.11] years). The euthymic BD group had 37 individuals (30 female; mean [SD] age, 25.12 [3.81] years). In the new sample, 8 clusters of RE-related activity, including left vlPFC activity, showed a positive association with mania/hypomania risk, which remained after excluding individuals with MDD history and was specific to mania/hypomania risk. In the test samples, this association was shown in test sample 1 only (β, 0.21; 95% CI, 0.08-0.35; P = .002; q(false discovery rate [FDR]), 0.006; R2, 0.04). Test sample 2 had a higher proportion with MDD history (49 of 65 [75.3%] compared to 31 of 52 [59.6%] in sa","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"274-284"},"PeriodicalIF":22.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}